KRAS mutations and NRAS Q61 predict worse outcomes in MM. (A) Survival curves comparing the clinical outcome of newly-diagnosed MM patients with and without activating RAS mutations (CoMMpass release IA11). (B) KRAS-mutated MM patients vs all other patients. (C) Activating KRAS vs NRAS mutations. (D) Codon-61 NRAS mutations vs other NRAS variants. All analyses were performed at VAF cutoffs of 0 and 0.3 to assess the effect of tumor heterogeneity on survivorship, with 0.3 as a signifier of a largely dominant RAS-mutated clone for this heterozygous mutation. P values from log-rank test and the sample size for each group are reported.
Figure 5.

KRAS mutations and NRAS Q61 predict worse outcomes in MM. (A) Survival curves comparing the clinical outcome of newly-diagnosed MM patients with and without activating RAS mutations (CoMMpass release IA11). (B) KRAS-mutated MM patients vs all other patients. (C) Activating KRAS vs NRAS mutations. (D) Codon-61 NRAS mutations vs other NRAS variants. All analyses were performed at VAF cutoffs of 0 and 0.3 to assess the effect of tumor heterogeneity on survivorship, with 0.3 as a signifier of a largely dominant RAS-mutated clone for this heterozygous mutation. P values from log-rank test and the sample size for each group are reported.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal